

***Amendments to the Claims***

This listing of claims will replace all prior versions and listings of claims in the application.

1.- 8. (cancelled)

9. (previously presented) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4).

10. - 15. (cancelled)

16. (previously presented) The composition of claim 9, further comprising a pharmaceutically acceptable carrier.

17. - 24. (cancelled)

25. (previously presented) A composition comprising

i) an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4); and

ii) one or more moieties selected from the group consisting of:

(a) a T helper peptide;

(b) a lipid; and

(c) a different peptide that induces a cytotoxic T lymphocyte response,

wherein said immunogenic peptide is linked to said one or more moieties.

26. (previously presented) The composition of claim 25, further comprising a pharmaceutically acceptable carrier.

27. (previously presented) The composition of claim 25, further comprising a liposome.

28. (previously presented) The composition of claim 25, wherein said one or more moieties is a T helper peptide.

29. (previously presented) The composition of claim 25, wherein said one or more moieties is a lipid.

30. (previously presented) The composition of claim 25, wherein said one or more moieties is a different peptide that induces a cytotoxic T lymphocyte response.

31. (previously presented) The composition of claim 9, further comprising a liposome.

32. (previously presented) The composition of claim 9, further comprising an antigen presenting cell (APC).

33. (previously presented) The composition of claim 25, further comprising an antigen presenting cell (APC).

34. (previously presented) The composition of claim 9, further comprising a dendritic cell.

35. (previously presented) The composition of claim 25, further comprising a dendritic cell.

36. (new) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4); and further comprising a T helper peptide, and wherein said immunogenic peptide is linked to said T helper peptide.

37. (new) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4); and further comprising a lipid, and wherein said immunogenic peptide is linked to said lipid.

38. (new) A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4); and further comprising a different peptide that induces a cytotoxic T lymphocyte response, and wherein said immunogenic peptide is linked to said different peptide.